Business
UNIVERSAL IBOGAINE ENTERS DRUG SUPPLY AGREEMENT
UNIVERSAL IBOGAINE ENTERS DRUG SUPPLY AGREEMENT Canada NewsWire CALGA...
About this update from Universal Ibogaine Inc
[{"type":"text","content":"\n \n \n \n UNIVERSAL IBOGAINE ENTERS DRUG SUPPLY AGREEMENT\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n CALGARY, AB\n \n ,\n \n Jan. 26, 2022\n \n /CNW/ - Universal Ibogaine Inc. (TSXV: IBO) (\"\n \n UI\n \n \" or the \"\n \n Company\n \n \") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, is pleased to advise it has entered into an agreement (the \"\n \n agreement\n \n \") with Psygen Labs Inc. (\"\n \n Psygen\n \n \") to secure a supply of GMP ibogaine for use in its planned future clinical trial for opioid use disorder and ongoing ibogaine detox treatments at its clinics.\n \n \n \n \n \n \n \n \n \n UI is in process of finalizing its pre-clinical trial (\"\n \n pre-CTA\n \n \") submission to Health Canada, following which it intends to apply to undertake a clinical trial of ibogaine for use in treatment of opioid use disorder(s).  The final approval by Health Canada will require UI to have an approved, secure supply of GMP certified ibogaine to use in the eventual clinical trial process.  Psygen is a Canadian company based in\n \n Calgary\n \n and is a leader in the manufacture of a range of medical grade products being used in the emerging psychedelics-based psycho-therapy field of treatment of anxiety, depression and other mental health issues.\n \n \n The agreement covers basic terms as to pricing, manufacture, and delivery of ibogaine to UI, and a definitive drug supply agreement is to be finalized in the near future, incorporating such factors as the volume of ibogaine that will be required, based on the ultimate size of the of the patient group required for the planned clinical trials.\n \n \n \n \n \n Nick Karos\n \n - Universal Ibogaine CEO\n \n \n \n \n Nick Karos\n \n noted \"We are pleased to have secured a firm of Psygen's caliber as one of our key partners.  Ibogaine has been used in tribal ceremonies in\n \n Africa\n \n for centuries and has traditionally been sourced for medical use from the root bark of a shrub found in limited a...